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1. Introduction
Erectile dysfunction (ED) or (male) impotence is a sexual dysfunction characterized by the
inability to develop or maintain an erection of the penis [1]. There are various underlying
causes, such as a compromised cardiovascular system and diseases such as diabetes and
chronic kidney disease (CKD), many of which are medically treatable. The causes of erectile
dysfunction may be physiological or psychological [2]. Sexual function includes libido, penile
erection, ejaculation, and orgasm. While each of these parameters may be of concern to an
individual patient, the vast majority of men complain of ED. Testosterone deficiency frequently
is associated with decreased libido and ED. ED is a clinical problem that is underdiagnosed,
under-evaluated, and under-treated. The prevalence of ED increases with age, and it is
associated with multiple medical conditions including diabetes, hypertension, and heart
disease that also increase with age. ED is a highly prevalent and often underreported condition.
The prevalence of ED varies in different countries and approximately 100 million men
worldwide are estimated to be affected with ED. More than half of US men between the ages
of 40 and 70 years are estimated to have ED. The worldwide ED prevalence in men with
diabetes ranges from 27% to 75% and it is estimated that the prevalence of ED will double in
the next 25 years [3]. There is a strong link between ED and atherosclerotic disease due to the
fact that they share similar risk factors. In a study where patients referred for myocardial
perfusion single-photon emission computed tomography were screened for ED with a
questionnaire, it was found out that 54.8% of the patients had ED. Patients with ED showed
more severe coronary heart disease. In diabetic patients, ED has been shown to predict silent
coronary artery disease, and in asymptomatic men without cardiovascular risk factors or
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known vascular disease [4]. Nevertheless, the hypothesis that ED, as a manifestation of
autonomic neuropathy, may be linked with the lack of symptoms in a proportion of diabetic
patients with silent CAD cannot be excluded [4].
2. Causes of erectile dysfunction
ED arises as a result of a collision of many factors: physical, psychological, physiological and
biochemical abnormalities. The exact cause of ED is usually difficult to establish because it
normally results from an underlying condition such as diabetes and/or heart disease. ED can
also be caused by psychological conditions such as stress, depression and anxiety [5]. The
physiological mechanism of erection is a complex neurovascular phenomenon that depends
on neural, vascular, hormonal, and psychological factors. Integrated function of these factors
is essential for production of a normal erectile response [3]. Recent advances in the under‐
standing of functional anatomy and of neurovascular interactions have improved our under‐
standing of the pathophysiological mechanism of ED [3].
Figure 1. Possible causes, managements and treatment strategies of Erectile Dysfunction
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2.1. Aging
Aging has been considered to be one of the major reasons for decreased sexual functions, which
are also affected by a change in lifestyle, increased day-to-day stress, depression, diabetes and/
or other metabolic and endocrine disorders. Various medications such as antidepressants,
tranquilizers, hypnotics, antiandrogens and antihypertensive agents can also lead to the
downfall of the sexual functions [6, 7]. There is a close relationship between aging and ED [8].
Research shows that chances of developing ED increase with age and are due to several age-
related factors such as a reduction in nonadrenergic noncholinergic nerve endings in the penis
and decreased endothelial nitric oxide (eNOS) activity. The decreased activity of eNOS and
bioavailability of NO impairs corpus cavernosum relaxation which can be exacerbated by an
increased release of vasoconstrictors. These confounding events are responsible for the
increase in the contractile tone in the penile vasculature [9]. Testosterone is secreted in a
circadian manner in younger men, but diurnal fluctuation is reduced and may disappear in
aging men [10]. Whatever the initiating factor of ED, the ultimate common pathological process
is damage to smooth-muscle cells and an increase in the accumulation of fibrosis, which
decrease the vasodilator response. This increased accumulation of collagen with aging has
been observed in both human and rat corporal smooth muscle [11]. The increase in collagen
accumulation leads to a decrease in blood flow as measured by peak systolic velocity, and this
decrease of blood flow contributes to ED.
As men age, dysfunction of this complex process occurs with an increased incidence and
prevalence. The cause of this age-related erectile dysfunction is not well understood and likely
involves multifactorial alterations in the cavernosal endothelial cell lining, smooth muscle
cells, and synthesis or activity of NO [12].
2.2. Oxidative stress
Oxidative stress (OS) is one of the major contributory factors towards ED. There is a growing
interest among researchers regarding the role of oxidative stress in the pathophysiological
mechanism of ED. Oxidative stress occurs when there is an imbalance between pro-oxidants
and the ability of the antioxidants to scavenge excess reactive oxygen species (ROS) [3]. Penile
erectile tissue is formed by 2 dorsal corporal bodies known as the corpora cavernosa. The
cavernosal bodies are composed of sinusoidal spaces with a trabecular meshwork. These
spaces are lined by endothelium. Neural transmitters, such as acetylcholine, are released from
cavernosal nerve endings and stimulate the neuronal NOS (nNOS) enzyme, which leads to the
release of NO from the endothelium. Erectile function is mediated by both nNOS and endo‐
thelial NOS (eNOS) [13]. NO is the principal mediator of penile erection [13]. Erectile function
is dependent on relaxation of the cavernous smooth muscle, and its mechanism of action is
dependent on penile smooth muscle relaxation, mediated by NO. Decreased production or
absence of NO may play a major role in ED. Production decreases when the availability of
substrate for NOS is reduced. NO is a highly reactive free radical that undergoes nonenzymatic
reaction with the heme moiety of oxyhemoglobin or that reacts with free radicals, such as
superoxide anion, to form peroxynitrite [14]. The relationship between OS in the penis and age
related ED has only been recently investigated and it was shown that as one ages, free radicals
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are produced at a higher rate and their numbers increase in various vascular beds. These
mechanisms ultimately produce an ineffective relaxation in cavernosal tissue, which leads to
ED. NO interacts with superoxide to form peroxynitrite, which has been reported to play a
central role in atherogenesis [14]. Peroxynitrite reacts with the tyrosyl residue of proteins,
which inactivates superoxide dismutase (SOD) and Leads to decrease the removal of super‐
oxide [15]. Previous studies have shown that penises from old rats display an increase in
nitrotyrosine immunostaining which is a marker for peroxynitrite formation. Due to aging,
there is not enough SOD produced to balance superoxide anions produced in aged rat penises,
which is why their endothelium and corpus cavernosal smooth muscle display high amounts
of superoxide anions as opposed to those of younger animals. Therefore, as extracellular SOD
is transferred to aged rats, erectile dysfunction is restored because the superoxide anion
formation is reduced [5]. Oxidative and nitrosative stress is associated with infertility, and
directly involved in reproductive disorders as diverse as oocyte implantation, endometriosis,
and pre-eclampsia in women, and ED, sperm damage and motility in men [16]. NO is reported
to decrease the adhesion of platelets and leukocytes to the vascular endothelial cells. A reduced
NO concentration aggravates the adhesion of these cells to the endothelium and releases
substances (thromboxane A2 and leukotriens) that cause vasoconstriction. These substances
further aggravate ED [5].
Hypercholesterolemia is associated with increased ultrastructural predisposition to athero‐
sclerosis and decreased cavernosal smooth-muscle relaxation [17]. Increased cavernosal
superoxide levels in hypercholesterolemia may decrease the availability of NO, which may
lead to the development of ED. Decreased NO bioavailability in obesity-prone animals has
been shown to be due, in part, to increased OS [18]. Oxidative modification of LDL (oxLDL),
the major carrier of plasma cholesterol, plays a crucial role in hypercholesterolemia and
atherosclerosis development. LDL can undergo oxidative modification by superoxide and
peroxynitrite, and it accumulates in atherosclerotic plaques. OxLDL also increases the
production of caveolin-1 and its association with eNOS affecting the balance of NO and
superoxide generation by eNOS and uncoupling eNOS activity [18]. In human vascular
endothelial cells, oxLDL stimulates OS via induction of NAD(P)H oxidase [19].
2.3. The effects of cardiovascular disease, obesity, metabolic syndrome on erectile
dysfunction
Obesity is normally associated with generally accepted ED risk factors such as hypertension,
hyperlipidaemia, and diabetes but has recently been categorised as an independent cause of
ED. An age adjusted BMI has been found to be significantly high in men who have reported
severe ED as well as those that are sexually inactive, and this indicates that obesity is a strong
predictor of ED. In several analyses from previous studies, obesity remained a major inde‐
pendent predictor of increasingly severe ED [20]. Furthermore, Gazzaruso et al. (2004)
suggested that ED could be considered to be the most efficient predictor of silent coronary
heart disease (CHD) in a diabetic population, independently of glycometabolic control and ED
severity [4]. The interest that is currently being addressed to inflammatory markers is not
fortuitous, considered the link between obesity, type II diabetes mellitus and atherosclerotic
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cardiovascular disease, three pathological conditions increasingly recognized as having an
inflammatory genesis, and increasing the risk of ED [ 21].
Erectile dysfunction represents an early surrogate marker of forthcoming cardiovascular
disease (CVD) [22]. It has been hypothesized that ED becomes evident earlier than CVD
because the smaller penile arteries reach critical narrowing, with insufficient blood flow, earlier
than larger vessels [23].
The recognition of ED, focusing attention on risk profile, could be of help in the prevention of
CVD. ED can be used to screen for the presence of hypogonadism, metabolic syndrome,
hypertension and silent CVD [24].
Abnormalities of the vasodilator system play an important role in the pathophysiology of ED
as it is now recognized as a common cause of ED [25, 26]. Therefore, the earliest events in the
development of atherosclerosis (endothelial dysfunction) are similar to the earliest events in
the development of ED [27] have suggested that a diagnosis of ED is a sentinel event that
should prompt investigation for CHD in asymptomatic men [27] Interestingly enough, Kaiser
et al [28] recently reported that subjects with ED but without evidence of clinical cardiovascular
disease and free of traditional cardiovascular risk factors present widespread abnormality of
endothelial function as has been seen in patients with cardiovascular risk factors. Thus, many
patients with ED seem to have a vascular mechanism similar to that seen in atherosclerosis [29].
2.4. Smoking
Several studies were carried out in order to confirm that smoking is an independent risk factor
for ED [30]. An example being a study that excluded diabetic patients that was controlled for
other factors such as age, trauma history and hypertension concluded that smoking is
independently associated with atherosclerosis in the pudendal artery. Tengs and Osgood
carried out study in 2001 and reported that 40% of impotent men were current smokers as
opposed 28% men in the general population [30]. Cross-sectional studies have reported that
smoking is an independent risk factor for ED.
2.5. Diabetes mellitus
Over the years, diabetes mellitus has been known as one of the major direct causes of ED.
Research has proved that the probability of ED occurrence is higher in diabetic men than non-
diabetic men of the same age and that this difference increases with age. In previous studies,
it has been estimated that 50%-75% of men with diabetes have ED [32]. Most of the vascular
complications that are linked to both Type l and Type ll diabetes are a result of hyperglycaemia,
but the majority of studies apply to Type l diabetes. The impairment of NOS activity and the
numerical reduction of nerves containing NOS are the reasons behind diabetes-associated ED.
Neurogenic and endothelium controlled relaxation of the smooth muscle as well as the
downregulation of mediators downstream from NO such as cGMP and cGMP-dependent
protein kinase in the corpus cavernosum are also involved in ED caused by diabetes [33].
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ED is an important component of the metabolic or insulin resistance syndrome, as demon‐
strated by inadequate vasodilation and/or paradoxical vasoconstriction in coronary and
peripheral arteries in response to stimuli that release NO [34]. Metabolic actions of insulin to
promote glucose disposal are augmented by vascular actions of insulin in endothelium to
stimulate production of the vasodilator NO [8]. Metabolic insulin resistance is characterized
by pathway specific impairment in PI3K-dependent signalling, which may cause imbalance
between production of NO and secretion of ET-1 in the endothelium, leading to decreased
blood flow, which exacerbates insulin resistance [17]. Deficiency of endothelial-derived NO is
believed to be the primary defect that links insulin resistance and ED. NO deficiency results
from decreased synthesis and/or release, in combination with exaggerated consumption in
tissues by high levels of reactive oxygen (ROS) and reactive nitrogen (RNS) species, which are
produced by cellular disturbances in glucose and lipid metabolism. ED contributes to impaired
insulin action, by altering the transcapillary passage of insulin to target tissues. Reduced
expansion of the capillary network, with attenuation of microcirculatory blood flow to
metabolically active tissues, contributes to the impairment of insulin stimulated glucose and
lipid metabolism. This establishes a reverberating negative feedback cycle in which progres‐
sive ED and disturbances in glucose and lipid metabolism develop secondarily to the insulin
resistance [35]. Studies were done on rats to show that transfer of the adenovirus mediated
gene of eNOS to the diabetic rat penis can improve the decreased erectile response by causing
an increase in cGMP formation [36]. An additional reason for the decreased eNOS activity in
the diabetic rat penis is that there is a reduced L-arginene content. A study was carried out in
which diabetic rats were orally administered L-arginine, and results indicated increased
endothelium dependent relaxation of cavernosal tissue by improvment of the biosynthesis of
NO which ultimately led to an increased erectile response [37].
2.6. Hormonal control on erectile dysfunction
There may be a link between insulin resistance, endothelial dysfunction, metabolism syn‐
drome, ED, and diabetes [35]. Hypogonadism has been shown to be an independent determi‐
nant of endothelial dysfunction, thus contributing to vascular pathology, including ED [35].
Testosterone (T) and its metabolites, dihydrotestosterone (DHT) and estradiol (E2), have a
critical role in the development and maintenance of normal male genitalia, testes, accessory
sex organs, skeletal muscle mass, bone growth mass, male hair patterns, libido and erectile
function [38]. Testosterone is also thought to influence central nervous system gender identi‐
fication [39]. DHT as well as testosterone can maintain libido and erectile function, indicating
that estrogen is not required for their maintenance in men [40]. Androgen receptors (ARs) are
present in the amygdala, lateral septum, and premamillary bodies in male primates [41]. AR
linked brain sites in the hypothalamus, pituitary gland and preoptic areas appear to influence
male sexual behaviour. For instance, stimulation of forebrain, hippocampus, and hypothala‐
mic nuclei causes penile erection and/or mating behaviour in laboratory animals [42, 43]. Other
studies indicate that the hypothalamic paraventricular nuclei could be the main source of a
descending spinal erection pathway to the spinal erection generator [44].
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Several studies have shown that acute administration of T induces rapid relaxation in vascular
tissues of different species including humans [45, 46] suggesting a non-genomic effect of this
hormone on vasomotion [47]. Different mechanisms have been proposed to explain T-induced
vasodilatation, [48] but as to which are the effective mechanisms and which are the mediators
involved with the T-induced vasorelaxation remain a matter of debate. Testosterone might
induce relaxation in human isolated corpora cavernosa strips by activation of smooth muscle
adenosine triphosphatesensitive K(+) channels. This finding suggests that T, in addition to its
known endothelial action, might regulate erectile function locally by its action on the smooth
muscle of the human corpus cavernosum [49 It has been established that different thresholds
exist for sexual desire and erectile function in humans, the former being quite higher than the
latter [50]. In humans, T deficiency determines a sequence of molecular penile events leading
to reduced capacity of smooth muscle and endothelial cells to relax in addition to causing
increased sensitivity to contractile factors, that is, alpha-adrenergic agonists and deficiency of
NO-induced relaxation during sexual stimulus. Recent evidence in humans suggest that T may
directly control the expression and activity of phosphodiesterase type 5 (PDE5) in human
corpus cavernosum so that in some selected patients, that is, total-T < 10 nmol/L and/or free-
T below 200 nmol/L, androgen supplementation may improve therapeutic efficacy to PDE5-i
[8]. Reduced production of testosterone may increase the risk of osteoporosis, sexual dysfunc‐
tion, fatigue, cardiovascular disease and mood disturbances, and may decrease muscle mass
[51]. Hypogonadism may be classified as hypergonadotrophic in cases of testicular failure or
hypogonadotrophic in cases of hypothalamic/pituitary failure [51]. Finally, penile NO, the
major smooth muscle relaxer responsible for penile erections, is in part regulated by testos‐
terone. To date, it is not known if the peripheral androgenic effects observed in animals also
are present in man 52].
3. Mechanisms
Various mechanisms may disturb the regulatory function of eNOS and endothelial NO
bioavailability, resulting in vasculogenic ED. As molecular mechanisms of normal erectile
function and the pathways leading to vasculogenic ED associated with eNOS are becoming
clearer, it seems that eNOS roles in the vascular pathophysiology of the penis are complicated
and not always uniform. For example, eNOS phosphorylation in the penis is ineffectively
regulated with aging and diabetes, although by different mechanisms. However, increased
oxidative stress in the penis seems to be a common component of vasculogenic ED, and
activation of the RhoA/ Rho-kinase contractile pathway is seen in several vasculogenic ED
states [53].
4. Management and treatments of erectile dysfunction
Erectile dysfunction is a defect of penis reaching and or sustaining erection because of
physiological or psychological factors [2]. Different treatments have been proposed including:
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• Psychological/behavioural therapy with a trained counsellor aimed at helping people to
address feelings of anxiety, fear and guilt that may have an impact on sexual function;
• Pharmacological and drug treatments (e.g testosterone replacement therapy for cases of
androgen insufficiency
• Phytomedical treatment
• Surgical treatment
4.1. Behaviour therapy of erectile dysfunction
When there is no obvious medical etiology for ED, psychosocial factors should be explored.
The potential clue that psychosocial factors may be a cause is that a man is able to achieve
normal erections and orgasm through masturbation or sexual stimulation with a partner other
than the “index case” partner with whom he has ED (e.g., a spouse with whom there is
substantial conflict). Group or individual cognitive behaviour therapy, psychosexual therapy,
including sensate focus technique and therapy aimed at improving relationship difficulties
(couple’s theraphy) may help to improve sexual dysfunction in men. In some cases, education
about medical and psychosocial etiologies of ED in conjunction with a physician reassurance
may prove adequate to restore normal male sexual function [54]. Lifestyle interventions
focused on modifiable health behaviours may be a safe strategy to improve ED.
4.2. Pharmacotherapeutic treatment of erectile dysfunction
Pharmacology of current and future therapies of erectile dysfunction depend on risk factors
and conditions associated with it. Different kinds of administration have been proposed such
as intracavernosal administration and non intracavernosal administration [55].
Clinical studies and experimental studies have showed positive and negative effects of the
different methods of administration [55]. Pharmacotherapy involves locally acting vasoactive
drugs such as papaverin and alprostadil [56] and firstline oral therapy for ED includes
phosphodiesterase type 5 (PDE-5) inhibitors such as sildenafil, vardenafil, and tadalafil, which
inhibit hydrolysis of the second messenger cyclic guanosine monophosphate (cGMP), the
production of which is promoted by NO release within the penile smooth cells [57, 58]. Various
centrally acting drugs influence sexual behaviour. In particular, the dopaminergic substance
apomorphine is a central enhancer that acts in the paraventricular nucleus of the hypothalamus
as a dopamine (D2) receptor agonist, inducing and increasing penile erection responses
following sexual stimulation via disinhibition [59].
PDE5 inhibitors have had a tremendous impact on the treatment of ED, but are not always
effective (e.g., in patients with diabetes) [55]. Common adverse events with PDE inhibitors
include headache (10–16%), flushing (5–12%), dyspepsia (4–12%), nasal congestion (1–10%),
and dizziness (2–3%) occurring during treatment [60]. The most successful approach to treat
ED has been drugs aimed at mechanisms in the target organ. Despite significant progress, the
different mechanisms involved in neurotransmission, impulse propagation, and intracellular
transduction of neural signals in penile smooth muscles need further investigation. It should
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be remembered that most of the pharmacological options for ED treatment do not influence
the progress of the underlying pathophysiology and do not cure the disease [55].
Testosterone therapy has been shown to normalize serum testosterone levels in patients with
hypogonadism. Testosterone therapy was aimed at maintaining or restoring libido and erectile
function; improving or maintaining virilization, muscle mass, strength, and bone density; and
to alleviate other symptoms related to hypogonadism. There is some evidence that the addition
of type 5 phosphodiesterase inhibitor can potentiate the effects of testosterone replacement in
some hypogonadal men [8]. If this is unsuccessful, one should consider other treatments for
ED. Because there are a wide range of pharmacotherapy options available, it would be
desirable, in many instances, to offer patients an alternative to current pharmacotherapy.
4.3. Effects of phytomedicinal plants on erectile dysfunction
A wide variety of human disorders is currently being treated with the use of plant materials
due to their decreased toxicity levels, cost-effectiveness as well as minimized side effects in
order to avoid drug resistance caused by pharmacological agents 61- 63].
Plants and herbs are persistently being studied for the identification of novel therapeutic
agents. Among the 250,000 higher plant species on earth, more than 80,000 plants have
medicinal values [62]. Herbal medicine is still the mainstay of about 75-80% of the global
population, mainly in developing countries, for primary health care because of better cultural
acceptability, better compatibility with the human body and lesser side effects. The chemical
constituents presenting the herbal medicine or plant are a part of the physiological functions
of living flora and hence they are believed to have better compatibility with human body [64].
A traditional system of Indian medicine called Ayurveda deals with the sexual dysfunctions
in a special category of treatment under the name „Vajikarna‟ or virilification. The system
includes the use of aphrodisiacs for erectile dysfunction, spermatogenesis, semenogenesis, and
methods of improving defective semen, causes of infertility, reproduction and sexual satis‐
faction [65].
About 317 phytochemicals are listed for antioxidant potential; 340 plants as aphrodisiac and
antioxidants and 40 plants are listed for adaptogenic nature. Ethnobotanical plants contain
antioxidant, aphrodisiac and adaptogenic properties [66].
Natural antioxidants are located in different parts of a plant such as wood, bark, stems, pods,
leaves, fruit, roots, flowers, pollen, and seeds [67]. Natural products, mainly phytomedicine,
or diet ingested by human, are antioxidants capable of terminating the free radical chain
reactions [68].
Antioxidant properties in plants are due to the presence of cinnamic acids, coumarins,
diterpenes, flavonoids, lignans, monoterpenes, phenylpropanoids, tannins and triterpenes
[69]. Phytochemicals like carotenoids, tocopherols, ascorbates and phenols presentin plants
are considered strong natural antioxidants and have an important role in health care system.
Phenols, a major group with antioxidant properties, comprise subclasses suchphenolic acid,
flavonoid, biflavonoid, anthocyanin andisoflavonoid [70]. Adaptogens found in plants
modulate response to stress (physical, environmental, or emotional) and help regulate the
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interconnected endocrine, immune, and nervous systems. This re-regulation of a disordered
or highly stressed system is achieved by metabolic regulators such as, catecholamines,
glucocorticoids, cortisol, serotonin, nitric oxide (NO), cholecystokinin, corticotrophin-
releasing factor (CRF), and sex hormones [71]. Chlorophytum borivilianum (Safed Musli) is often
referred to as Viagra without the side effects [71]. Safed musli contains saponin and alkaloids
which give musli its medicinal properties. Stigmasterol, a form of saponin is very similar in
structure to testosterone and consequently can occupy the testosterone receptor sites-door‐
ways to the cells acting like an aphrodisiac. Hecogenin has steroidal-like effects that help to
synthesize anabolic hormones. Anabolic hormones allow men to retain nitrogen more readily,
which helps form larger more bulging muscle during an erection.
Tribulus terrestris is a herb that has been used in the traditional medicine of China and India
for centuries. The active compounds in Tribulus are called steroidal saponins. The protective
effect of T. terrestris for Streptozotocin –induced diabetic rats may be mediated by inhibiting
oxidative stress [72]. Oral administration of 100 mg/kg of test drug has proven anabolic effect
as evidenced by body weight gain in the body and reproductive organs. Improvement in sexual
behaviour of male rats was characterized by increased amount and intromission frequency.
Penile erection index (PEI) was also considerably enhanced without any noticeable toxicity.
The testosterone level and sperm count also significantly increased. The results are comparable
to that of standard drug, sidenafil citrate. Findings of the present study validate the traditional
use of T. terrestris for its role in enhancing sexual behaviour and potential to be used in the
treatment of ED [73].
Ginseng is an essential constituent in traditional Chinese medicine for the treatment of sexual
impotence. It is likely that this effect reflects the tonic, restorative and adaptogenic properties.
It has been shown that ginsenosides relax rabbit corpus cavernosum and this effect is mediated
by nitric oxide, released from endothelial or neural cells. These endothelial and neurogenic
effects of ginsenosides in inducing relaxation of the corpus cavernosum may account for the
aphrodisiac effect of Panax ginseng [74].
Eriosema kraussianum Zulu indigenous plants are effective remedies for the treatment of ED
and/or impotence. Five pyranoisoflavones have been isolated from the rootstock of Eriosema
kraussianum and were screened for smooth muscle relaxation of rabbit penile muscle. The most
active of the compounds had an activity of 75% of that found in Viagra. In a test on ED rabbit
penile smooth muscle, it showed an activity close to that of Viagra, thus living up to the plant
its traditional use [75, 76].
Yohimbine is an alkaloid derived from the African yohimbe tree (Pausinystalia yohimbe). It
blocks the presynaptic α-2 adrenergic receptors in the brain, leading to reduction of brain and
spinal cord norepinephrine levels. Inhibition of sympathetic tone enhances sexual arousal and
NO release from penile nerves [77].
4.4. Surgical treatment
Patients who fail to respond to pharmacotherapy or those who want a permanent solution
usually have surgical implantations of penile prosthesis. These prosthetics can either be
inflatable or malleable, however most patients prefer the inflatable devices because they
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provide them with a sense of a natural erection. Inflatable devices are more expensive than
malleable devices with satisfaction rates of 70-87% reported from patients after appropriate
consultation [78].
Vacuum constriction devices apply negative pressure to the penis in order to draw venous
blood into the penis which is then retained by application of a visible constricting band at the
base of the penis (a method that seems preferable to older patients) [79]. This method yields a
successful erection for intercourse that can be rated as 90%. The satisfaction rates range
between 27-94% but about <30% of the patients discontinue use after 2years because of the
negative side effects that include penile pain, delayed ejaculation and numbness that occur.
Penile prosthesis can go wrong because there are two major complications involved, namely
mechanical failure and infection. Infection rate is therefore reduced by the use of antibiotic
prophylaxis or by using implants that are impregnated with antibiotics [80].
5. Conclusion and recommendations
Erectile dysfunction is an increasing global the incidence. ED is also indicative of more serious
cardiovascular, psychoactive disorders. Therapeutic interventions that are successful in
treating ED may be effective in treating the early stages of conditions that include atheroscle‐
rosis, angina, plaque rupture and diabetic angiopathy. One common pathological denomina‐
tor in both CVD and ED is oxidative stress, that is, the overproduction of ROS, in particular,
O2- and H2O2.Thus there is direct relationship between oxidative stress, sexual impotency and
psychoactive mechanisms that alters nitrogen oxide inhibition mechanisms significantly as
stated above. Therefore it is necessary to evaluate potential of natural herbs/ extracts to correct
disorders and disabilities evolved in the manifestation of ED. An ideal medicinal plant extract
and or natural product will achieve biochemical, physiological, pharmacological responses on
erectile dysfunction. However, because of the synergic or antagonistic effects of the contents
of the natural plants, herbs or their extract, it would be a worthy to investigate on their
bioavailability and properties in order to maximise their use. Moreover, further investigations
in the clinical setting and qualify for clinical trials in humans are warranted.
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